Reasons to take a look at ZEPOSIA® (ozanimod)
If you have relapsing MS, finding treatment that works best for you means knowing what treatment options are out there. Discover a once-daily pill for people living with relapsing MS: ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if ZEPOSIA is safe and effective in children.
Here are 5 things to know about ZEPOSIA.
1. ZEPOSIA is a once-daily pill
Unlike many treatments for MS, ZEPOSIA is a pill that you take once a day.
2. ZEPOSIA was more effective than a leading injectable medicine (Avonex)*
More than 1,700 people participated in two clinical studies, combined. That's the largest number of people in two studies that compared one MS medication to another.
*Avonex (interferon beta-1a).
In a one-year study, people who took ZEPOSIA had 48% fewer relapses than people who took a leading injectable medicine. And, in a two-year study, people who took ZEPOSIA had 38% fewer relapses than with a leading injectable.†
†In the one-year study, people taking ZEPOSIA had an Annualized Relapse Rate (ARR) of 0.181 vs 0.350 with a leading injectable. In the two-year study, people taking ZEPOSIA had an ARR of 0.172 vs 0.276 with a leading injectable. To measure relapses, the Annualized Relapse Rate was used, which is the average number of relapses a group of people have in one year. A total of 895 people were in the one-year study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in the two-year study (ZEPOSIA 433, a leading injectable 441).
More people were relapse free
In the one-year study, 78% of people who took ZEPOSIA were relapse free at one year (versus 66% of people who took a leading injectable). And, in the two-year study, 76% of people who took ZEPOSIA were relapse free at two years (versus 64% of people who took a leading injectable).‡
‡A relapse was defined as new or worsening symptoms directly associated with MS that lasted more than twenty-four hours (after having a mostly stable neurological state for at least thirty days).
Fewer new or enlarging lesions (T2), too
The one-year study also showed that people taking ZEPOSIA had 48% fewer new or enlarging lesions (T2) than people who took a leading injectable medicine. And, in the two-year study, people taking ZEPOSIA had 42% fewer new or enlarging lesions (T2) than with a leading injectable.§
§In the one-year study, people taking ZEPOSIA had an average of 1.47 lesions (T2) vs 2.84 with a leading injectable. In the two-year study, people taking ZEPOSIA had an average of 1.84 lesions (T2) vs 3.18 with a leading injectable.
Disability progression was also measured
When taking ZEPOSIA or Avonex, 9 out of 10 people experienced no progression of physical disability. THERE WAS NO SIGNIFICANT DIFFERENCE in disability progression: 7.6% of people experienced disability progression with ZEPOSIA vs 7.8% with a leading injectable medicine. Physical disability progression was measured every 3 months and combined from both studies.
3. ZEPOSIA was also studied for safety
It's important to know as much about your medicine as you can, including information about its safety.
There were two studies—one lasting one year and another lasting two years. The studies looked at 882 people taking ZEPOSIA, and 90% of them stayed with the treatment for the entire clinical study. Of those who stopped taking ZEPOSIA, 3% did so because of a side effect they experienced. The rest left the studies for a variety of other reasons.
Possible serious side effects
These are the serious side effects reported by people who took ZEPOSIA during the clinical studies.
- Infections that can be life-threatening and cause death
- Slow heart rate when you start taking ZEPOSIA
- Liver problems
- Increased blood pressure
- Breathing problems, such as shortness of breath
- Macular edema (a vision problem)
- Swelling and narrowing of blood vessels in your brain
- Severe worsening of MS after stopping ZEPOSIA compared to before or during treatment
- Allergic reactions
To learn more about these side effects and the possible symptoms, please see the Important Safety Information below.
Most common side effects
During both of the clinical studies, people who took ZEPOSIA were asked to report any side effects that they experienced. These were the most common:
- Upper respiratory tract infections
- Elevated liver enzymes
- Low blood pressure upon standing
- Painful and frequent urination
- Back pain
- High blood pressure
These are not all of the side effects of ZEPOSIA. Please see the Prescribing Information (link below) for information on all of the side effects reported by those taking ZEPOSIA. If you experience any side effects while taking ZEPOSIA, be sure to talk to your doctor right away.
Please see the full Prescribing Information and Medication Guide for information on all of the side effects reported by those taking ZEPOSIA.
4. Doctors are encouraged by results with ZEPOSIA
“Once-daily oral dosing has held great appeal to my patients, and I am pleased with the clinical results seen with ZEPOSIA.”
—Edward J. Fox, MD, PhD
Director, Multiple Sclerosis Clinic of Central Texas ||
5. The ZEPOSIA 360 Support™ program will help you every step of the way
ZEPOSIA has a program to help guide you called ZEPOSIA 360 Support. You can talk to an MS Nurse Navigator about treatment with ZEPOSIA, navigating insurance benefits, assistance with financial support, and much more. You can call 1-833-ZEPOSIA (833-937-6742), Monday to Friday, 8 AM - 8 PM ET.
Wondering if ZEPOSIA is right for you?
Your MS healthcare team can tell you even more about ZEPOSIA. Schedule an appointment to ask about ZEPOSIA and whether it’s right for you. Here are some questions you can ask your MS healthcare team.
And to learn even more about ZEPOSIA and the ZEPOSIA 360 Support program, visit ZEPOSIA.com.
||Paid medical consultant of BMS.